FMP
NASDAQ
2.29 USD
0.1 (4.37%)
Mr. George K. Ng Esq., J.D.
Healthcare
Biotechnology
https://www.processapharmaceuticals.com
NASDAQ
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, wh...
0001533743
US74275C3043
74275C205
7380 Coca Cola Drive
443 776 3133
US
15
Mar 7, 2014
0001533743
NASDAQ
Biotechnology
Healthcare
74275C205
US74275C3043
US
2.29
0.52
1.61M
3.91M
-
2.02-18.0
0.41
-
-
-
-
-0.1
-
https://www.processapharmaceuticals.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.